Invivo Therapeutics Holdings Corp (OTC:NVIV) has been climbing up progressively since last Friday. Yesterday, the stock 
added another 42% to its price and traded over 1.6 million shares.
The reason for the climb is easy to be explained. Over the past week, Invivo released series of positive news on its business, which immediately pumped up its stock price.
Though, despite the current uptrend for NVIV, it appears that the company decided to secure the gain by promotions. The campaign was held yesterday when NYC Marketing inc alerted on NVIV. The compensation for the promotion cost $20,000 and it was paid by Costa Point Ventures.
However, the most impressive about the stock alert was the statement that Invivo was awaiting the go-ahead from the FDA, meaning that the company has not received it yet.[BANNER]
Recently, NVIV filed its financial report. However, it was completely discouraging. Huge expenses, enormous operating loss and a shocking deficit accumulated during the development stage period. At the same time, the company’s cash position is not able to cover any of these, while NVIV keeps waiting for an FDA approval for its second product.
The management is optimistic that its cash will fund the operations through March 31, 2012. However, the team claims that Invivo will need to raise substantial additional capital to complete its clinical trials, obtain marketing approvals and commercialize its products.
